Marché mondial du traitement de l’hyperhidrose – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché du traitement de l'hyperhidrose

Le marché du traitement de l'hyperhidrose devrait connaître une croissance significative au cours de la période de prévision. L'hyperhidrose se produit lorsque le patient souffre de problèmes de transpiration extrêmes indépendamment des conditions environnementales et des exigences de thermorégulation. Les antisudorifiques en vente libre sont souvent la première ligne de défense contre la transpiration excessive. La toxine botulique de type A est un traitement sûr et efficace de l'hyperhidrose focale, qui dure plus longtemps que les traitements topiques et ne nécessite pas d'interventions chirurgicales invasives.

Data Bridge Market Research analyse le taux de croissance du marché mondial du traitement de l'hyperhidrose au cours de la période de prévision 2023-2030. Le TCAC attendu du marché mondial du traitement de l'hyperhidrose a tendance à être d'environ 5,60 % au cours de la période de prévision mentionnée. Le marché était évalué à 607,52 millions USD en 2022 et devrait atteindre 939,45 millions USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de recherche sur le marché de Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché du traitement de l'hyperhidrose

Market Definition

Hyperhidrosis disorders are typically characterized by excessive sweating. The excess of sweat in this condition is not even certainly associated with heat or exercise; it is related or concerned to medical abnormality. The extreme sweat occurs in areas of the body such as underarms, palms, face; some people feel the sweat in their shoes and are also unrelated to body temperature. The major cause of the diseases could be the neurologic, endocrine, infectious and other systemic diseases, but healthy people are also likely to report the sufferings from Hyperhidrosis disorders.

Global Hyperhidrosis Treatment Market Dynamics

Drivers

• Increasing Strategic Partnerships

The strategic partnerships and collaborations between several market players and associations are helping in the growth of the market. For instance, in April 2021, Fortress Biotech, partner company Journey Medicals, entered into a definitive agreement to acquire Qbrexza  in the USA from Dermira, a wholly-owned subsidiary of Eli Lilly. Therefore, the market is projected to witness growth. Though, the short-term results of cosmetic and therapeutic procedures are a major factor limiting the growth of the market.

• Growing R&D Activities

The latest R&D activities associated with the market are gaining attraction globally. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies that evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients having primary axillary hyperhidrosis. This boosts the market growth.

Opportunities

• Increase in Hyperhidrosis Cases

As per the study published in National Library of Medicine by Jared Brackenrich in October 2021, In the U.S, the incidence of this disorder is projected to be around 3%. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis. Thus, growing burden of hyperhidrosis expected to boost the demand for its treatment thus increase the market growth.

• Increasing Demand of Botox

According to the article published in International Hyperhidrosis Society of October 2020, Excessive sweating of the armpits, hands, feet, head, and face and other relatively small body areas can be treated with onabotulinumtoxin A. Botox has been shown to reduce sweating by 82-87%. The effects begin to show up 2 to 4 days post treatment, with the full effects generally appearing within two weeks. Dryness lasts 4 to 12 months on average, but few studies have found that it can last up to 14 months.

Restraints/Challenges

• Side Effects of Botox

Several side effects are associated with botox. Effects such as muscle weakness, vision problems, breathing problems that are deeply affecting the patients and thus hampering the market growth.

• High Cost

The huge expenditure of the treatment methods impede the market growth. Many times, due to lack of inappropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return cost heavy impact on their health. Thus, this is an important restrain that needs to be taken care of.

This global hyperhidrosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Hyperhidrosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hyperhidrosis Treatment Market

COVID-19 had a neutral impact on the market growth. According to the January 2021 published article titled, Paroxysmal hypothermia and hyperhidrosis with exacerbation after COVID‑19 infection, periods of hypothermia alternated with fever for four days. Although, after the recovery phase, episodic hyperhidrosis and hypothermia continued without fever despite the use of clonidine. Therefore, the demand for hyperhidrosis treatment has increased. According to the International Hyperhidrosis Society in May 2021, sweat could actually help prevent the transmission of COVID-19. Even in the post-pandemic era, the disease and its associated treatment continue rapidly.

Recent Development:

• In May 2022, Meruho launched Rapifort Wipes in Japan, used for the treatment of primary axillary hyperhidrosis. It is the first prescription wipe preparation in the country.
• In August 2021, Brickell Biotech, Inc. stated that the final patient had completed the Phase 3 pivotal Cardigan II study, which evaluates sofpironium bromide gel, 15% in patients with primary axillary  hyperhidrosis

Global Hyperhidrosis Treatment Market Scope

The global hyperhidrosis treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Axillary Hyperhidrosis
• Palmar Hyperhidrosis
• Plantar Hyperhidrosis

Treatment

• Oral Medications
• Anticholinergics
• Others
• Over the Counter Antiperspirants
• Surgery
• Lasers
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hyperhidrosis Treatment Market Regional Analysis/Insights

The global hyperhidrosis treatment market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global Hyperhidrosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to favorable healthcare infrastructure, high per capita income, and high rate of adoption of advanced surgeries in the region.

Asia-Pacific dominates the market due to the promotion of research & development activities and awareness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hyperhidrosis Treatment Market Share Analysis

The global hyperhidrosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hyperhidrosis treatment market.

Key players operating in the global hyperhidrosis treatment market include:

• GSK Plc (U.K.)
• TheraVida (U.S.)
• Revance (U.S.)
• NovaMedica. (Russia)
• Ulthera, Inc. (U.S.)
• DEMIRA e.V (Germany)
• Abbvie, Inc (U.S.)
• Fresh Tracks Therapeutics, Inc. (U.S.).
• Dr. August Wolff GmbH (Germany)
• Dermavant Sciences, Inc. (U.S.)
• Eirion Therapeutics, Inc (U.K.)
• Kaken Pharmaceutical Co., Ltd. (Japan)
• Intas Pharmaceuticals Ltd. (India)
• Roivant Sciences Ltd (Switzerland)

SKU-56648